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The hereditary spastic paraplegias (HSPs) are genetically heterogeneous disorders characterized by progressive lower-
extremity weakness and spasticity. The molecular pathogenesis is poorly understood. We report discovery of a
dominant negative mutation in the NIPA1 gene in a kindred with autosomal dominant HSP (ADHSP), linked to
chromosome 15q11-q13 (SPG6 locus); and precisely the same mutation in an unrelated kindred with ADHSP that
was too small for meaningful linkage analysis. NIPA1 is highly expressed in neuronal tissues and encodes a putative
membrane transporter or receptor. Identiﬁcation of the NIPA1 function and ligand will aid an understanding of
axonal neurodegeneration in HSP and may have important therapeutic implications.
Ten loci for autosomal dominant hereditary spastic par-
aplegia (ADHSP) have been mapped, and four ADHSP
genes have been identiﬁed: SPG4/spastin, SPG3A/atlas-
tin, SPG13/chaperonin 60, and SPG10/KIF5A (Hazan
et al. 1999; Zhao et al. 2001; Hansen et al. 2002; Reid
et al. 2002). (For reviews of hereditary spastic paraplegia
[HSP] [“Stru¨mpell-Lorrain syndrome,” MIM 182600],
see Fink and Hedera 1999; Fink 2001, 2002; Reid
2003.) Despite these advances, the molecular pathophy-
siology of the ADHSPs is largely unknown. Elsewhere,
we identiﬁed a locus for uncomplicated ADHSP in chro-
mosome 15q (SPG6) (Fink et al. 1995a; 1995b). We
now report identiﬁcation of disease-speciﬁc mutations
in a novel gene, NIPA1 (ﬁg. 1a) in the original SPG6-
linked kindred (Fink et al. 1995a) and in an unrelated
kindred with ADHSP (ﬁg. 1b).
The SPG6 locus extends 6.1 cM between D15S128
and the centromere (Rainier et al. 2000) (ﬁg. 2a), an
interval often involved in deletions that result in Prader-
Willi syndrome (PWS) or Angelman syndrome (AS).
PWS and AS are characterized by genetic imprinting, a
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phenomenon in which gene expression and the pheno-
type depend on the sex of the transmitting parent (Nich-
olls and Knepper 2001). We analyzed a large kindred—
ADHSP-ARK1 (ﬁg. 1b), in which ADHSP was linked to
the SPG6 locus—and found no evidence of genetic im-
printing (Fink et al. 1995a). Therefore, we analyzed as
SPG6 candidates the four unique, nonimprinted, and
highly evolutionarily conserved genes mapped proximal
to the imprinted domain and within the pericentromeric
region of chromosome 15q (Chai et al. 2003 [in this
issue]). These candidate genes included nonimprinted in
Prader-Willi/Angelman loci 1 (NIPA1) (NCBI accession
number BK001020) and 2 (NIPA2) (NCBI accession
number BK001120) (Chai et al. 2003 [in this issue]),
GCP5 (NCBI accession number AF272884) (Murphy
et al. 2001), and CYFIP1 (NCBI accession number
NM_014608) (Koybayashi et al. 1998; Schenk et al.
2001).
We identiﬁed a nucleotide substitution at position 159
of the NIPA1 cDNA (159CrG; ﬁg. 1a), which resulted
in an amino acid substitution at position 45 of the NIPA1
protein (T45R) in each affected subject ( ) innp 28
ADHSP-ARK1 (ﬁg. 1b). In contrast, each unaffected sub-
ject ( ) had only C at this position (ﬁg. 1b), whichnp 17
agrees with the known human genomic sequence (NCBI
accession number NT_024668). We examined 105 con-
trol subjects (ascertained through the Elderly SubjectsPro-
gram of the University of Michigan Institute of Geron-
tology). Each control subject had only C at position 159
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Figure 1 a, Representative SPG6 sequence of normal and affected subjects from the ADHSP-ARK and ADHSP-IRQ kindreds. PCR
products (from 50 ng of DNA) were puriﬁed through Sephadex G-50 columns, were analyzed by agarose gel electrophoresis, and were sequenced
either by use of the ABI PRISM dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems) on an ABI PRISM
3100 Genetic Analyzer, according to the manufacturer’s instructions, or through the University of Pennsylvania DNA sequencing facility. The
arrows mark the position of the NIPA1 mutation (cDNA nucleotide 159). b, Pedigrees of ADHSP-ARK1 and ADHSP-IRQ1. Letters refer to
sequence at nucleotide 159 of the NIPA1 cDNA sequence. Clinical features (Fink et al. 1995a), muscle biopsy (Hedera et al. 2000 ), and genetic
features (Fink et al. 1995b) of ADHSP-ARK1 have been reported elsewhere. The ADHSP-IRQ1 kindred was ascertained through the University
of Michigan Neurology Outpatient Clinic.
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Figure 2 a, SPG6 occurs in regions deleted in PWS and AS. SPG6 is mapped to chromosome 15q11, proximal to the imprinted PWS
and AS domains, within a region containing four nonimprinted genes. These genes, including NIPA1, map within class I deletions in patients
with PWS and AS but are intact in class II deletions (Chai et al. 2003 [in this issue]). BP p breakpoint hotspot; cen p centromere; tel p
telomere. b, NIPA1 secondary structure analysis. Nine predicted transmembrane (TM) domains (Chai et al. 2003 [in this issue]) are shown.
The NIPA1 T45R mutation occurs at the interface of TM1 and the ﬁrst putative outside loop. c, Expression of NIPA1 by northern blot analysis.
NIPA1 transcripts of 2.2 kb and 7.5 kb are found in all tissues but are greatly enriched in neuronal tissues. Probes were prepared from TA-
cloned RT-PCR products of human NIPA1 (167 bp) and exons 2–3 of the control SNURF-SNRPN gene, were labeled with a-32P-dCTP, and
were hybridized in ExpressHyb (Clontech) at 65C to northern blots (Clontech), according to the manufacturer’s protocol.
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of the NIPA1 cDNA (data not shown). We analyzed the
coding sequence of the other three nonimprinted genes
(GCP5, CYFIP1, and NIPA2) in two affected members
of ADHSP-ARK1 and identiﬁed no disease-speciﬁc mu-
tations (data not shown). We then analyzed the NIPA1
coding sequence in affected probands from 62 kindreds
with ADHSP, 6 kindreds with probable autosomal reces-
sive HSP, and 13 subjects with all the signs and symptoms
of HSP but no family history (“apparently sporadic” spas-
tic paraplegia). Affected subjects in one unrelated kindred
(ADHSP-IRQ1) (ﬁg. 1b) had precisely the same NIPA1
mutation (159CrG) (ﬁg. 1b) as affected subjects in
the ADHSP-ARK1 kindred. Unaffected subjects from
ADHSP-IRQ1 kindred showed only the normal nucle-
otide (159C). Whereas the ADHSP-ARK1 kindred was
linked to the SPG6 locus (Fink et al. 1995b), the
ADHSP-IRQ1 kindred was too small for meaningful
linkage analysis. Clinical features of the ADHSP-ARK1
affected individuals are typical of uncomplicated HSP of
late-teenage to early-adult symptom onset (Fink et al.
1995a). Clinical features of ADHSP-IRQ1 were similar:
onset of insidiously progressive spastic weakness in both
legs that began in late teen-age years and was associated
with urinary urgency and mild vibratory sensation im-
pairment in the toes.
Kindreds ADHSP-ARK1 and ADHSP-IRQ1 are of
Irish and Iraqi ancestry, respectively. Analysis of hap-
lotypes for polymorphic markers linked to this lo-
cus (D15S541, D15S542, D15S646, D15S817, and
D15S1021) showed no evidence of haplotype sharing
between ADHSP-ARK1 and ADHSP-IRQ1 kindreds
(data not shown). This indicates that these two kin-
dreds with ADHSP are not closely related and suggests
that the same NIPA1 mutation arose independently
in each of them.
Disease-speciﬁc NIPA1 mutations in ADHSP-ARK1
and ADHSP-IRQ1 occur in NIPA1 exon 1 and are pre-
dicted to change threonine to arginine at amino acid
position 45 (T45R) (ﬁg. 2b). This amino acid is con-
served in mouse, chicken, and ﬁsh (zebraﬁsh and Fugu)
(Chai et al. 2003 [in this issue]; R.D.N., unpublished
data) and is predicted to occur at the end of the ﬁrst of
nine transmembrane domains in the NIPA1 polypeptide
(ﬁg. 2b). NIPA1 does not contain an AAA domain (like
that present in spastin [Hazan et al. 1999]) or a GTPase
domain (like that present in atlastin [Zhao et al. 2001])
and does not bear other homology to genes that cause
other forms of HSP. Although the NIPA1 function is not
known, the clear prediction based on hydrophobicity
analysis of an integral membrane-associated protein
(Chai et al. 2003 [in this issue]) suggests that NIPA1
functions as a receptor or transporter. Many individuals
with PWS or AS have chromosome 15q class I deletions
that include NIPA1 (ﬁg. 2a) (Chai et al. 2003 [in this
issue]). The fact that such individuals do not exhibit
progressive spastic paraplegia indicates thatNIPA1 hap-
loinsufﬁciency does not cause progressive spastic para-
plegia. Therefore, we suggest that the NIPA1 T45R mis-
sense mutation identiﬁed in these kindreds with ADHSP
is pathogenic through a dominant negative, gain-of-
function mechanism.
NIPA1 mRNA is expressed constitutively at low levels
with 2.2-kb and 7.5-kb transcripts in all human tissues
but shows signiﬁcant enrichment in the brain (ﬁg. 2c).
The latter expression pattern is found throughout the
CNS, whereas spinal cord shows equal expression of the
two NIPA1 mRNAs (ﬁg. 2c). The alternative mRNA
isoforms arise from alternative polyadenylation within
NIPA1 exon 5, and equivalent expression patterns are
found for mouse (Chai et al. 2003 [in this issue]).
Our observations of the same NIPA1 gene mutation
(159 CrG; T45R) in two unrelated kindreds with
ADHSP that disrupts an interspecies conserved amino
acid and was absent in control subjects ( )np 105
strongly support the pathogenic signiﬁcance of this mu-
tation. Discovery of NIPA1 mutations as the cause of
SPG6-linked HSP improves the ability to diagnose HSP
and to provide genetic counseling. The presence of a
dominant negative NIPA1 mutation in a putative mem-
brane receptor or transporter suggests that SPG6 arises
from either altered signal transduction or small-molecule
transport through a membrane. We suggest that this
property makes NIPA1 and its unknown ligand an at-
tractive target for therapeutic intervention in SPG6 and,
perhaps, in other spastic paraplegias. Identiﬁcation of
the NIPA1 cellular and subcellular localization, function,
and ligand will therefore aid an understanding of axonal
neurodegeneration in HSP and may have important ther-
apeutic implications.
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